New progress of allogeneic transplantation in myelodysplastic syndromes in the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2014.02.004
- VernacularTitle:骨髓增生异常综合征同种异基因移植研究新进展:第55届美国血液学会年会报道
- Author:
Xudong TANG
;
Feng LIU
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2014;23(2):73-74,78
- CountryChina
- Language:Chinese
-
Abstract:
New progress of myelodysplastic syndomes (MDS) in the 55th ASH annual meeting on allogeneic transplantation were reviewed.Even though the IPSS was developed mainly to determine the prognostic risk in newly diagnosed MDS patients,its predictive value concerning posttransplantation outcome has bcen confirmed in several studies.According to a decision model published a decade ago,patients with intermediate-2 or high-risk MDS by IPSS criteria should be considered for hematopoietic cell transplantation (HCT) at the time of diagnosis if an HLA-matched donor is available at this time.Given the age of most MDS patients,therapeutic interventions are per se often limited to rather nonintensive treatment approaches.This article reviews the current evidence for allogeneic HCT as a therapeutic option in the context of disease-specific characteristics and current available alternative treatments.
